AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)
Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%
AbbVie total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
AbbVie's total debt was $70.82B at Jun 30, 2026. For fiscal 2025 it was $67.50B, up 0.5% from the year before. Over ten years it grew 7.9% a year on average. The highest annual figure on record is $86.06B in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.50B | +0.5% |
| FY2024 | Dec 31, 2024 | $67.14B | +13.1% |
| FY2023 | Dec 31, 2023 | $59.39B | -6.1% |
| FY2022 | Dec 31, 2022 | $63.27B | -17.5% |
| FY2021 | Dec 31, 2021 | $76.68B | -10.9% |
| FY2020 | Dec 31, 2020 | $86.06B | +29.0% |
| FY2019 | Dec 31, 2019 | $66.73B | +65.5% |
| FY2018 | Dec 31, 2018 | $40.31B | +7.9% |
| FY2017 | Dec 31, 2017 | $37.37B | +1.4% |
| FY2016 | Dec 31, 2016 | $36.84B | +16.3% |
| FY2015 | Dec 31, 2015 | $31.67B | +111.5% |
| FY2014 | Dec 31, 2014 | $14.98B | +1.7% |
| FY2013 | Dec 31, 2013 | $14.72B | -6.1% |
| FY2012 | Dec 31, 2012 | $15.67B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $70.82B | +0.5% |
| Q1 FY2026 | Mar 31, 2026 | $72.86B | +4.2% |
| Q4 FY2025 | Dec 31, 2025 | $67.50B | +0.5% |
| Q3 FY2025 | Sep 30, 2025 | $68.74B | -3.3% |
| Q2 FY2025 | Jun 30, 2025 | $70.48B | -0.2% |
| Q1 FY2025 | Mar 31, 2025 | $69.89B | -5.6% |
| Q4 FY2024 | Dec 31, 2024 | $67.14B | +13.1% |
| Q3 FY2024 | Sep 30, 2024 | $71.08B | +17.0% |
| Q2 FY2024 | Jun 30, 2024 | $70.63B | +15.8% |
| Q1 FY2024 | Mar 31, 2024 | $74.00B | +19.2% |
| Q4 FY2023 | Dec 31, 2023 | $59.39B | -6.1% |
| Q3 FY2023 | Sep 30, 2023 | $60.75B | -12.7% |
| Q2 FY2023 | Jun 30, 2023 | $61.02B | -16.3% |
| Q1 FY2023 | Mar 31, 2023 | $62.09B | -15.5% |
| Q4 FY2022 | Dec 31, 2022 | $63.27B | -17.5% |
| Q3 FY2022 | Sep 30, 2022 | $69.61B | -13.8% |
| Q2 FY2022 | Jun 30, 2022 | $72.93B | -11.2% |
| Q1 FY2022 | Mar 31, 2022 | $73.47B | -14.1% |
| Q4 FY2021 | Dec 31, 2021 | $76.68B | -10.9% |
| Q3 FY2021 | Sep 30, 2021 | $80.72B | -7.3% |
| Q2 FY2021 | Jun 30, 2021 | $82.14B | -6.1% |
| Q1 FY2021 | Mar 31, 2021 | $85.53B | +27.6% |
| Q4 FY2020 | Dec 31, 2020 | $86.06B | +29.0% |
| Q3 FY2020 | Sep 30, 2020 | $87.06B | +126.7% |
| Q2 FY2020 | Jun 30, 2020 | $87.43B | +134.7% |
| Q1 FY2020 | Mar 31, 2020 | $67.05B | +80.5% |
| Q4 FY2019 | Dec 31, 2019 | $66.73B | +65.5% |
| Q3 FY2019 | Sep 30, 2019 | $38.40B | -5.2% |
| Q2 FY2019 | Jun 30, 2019 | $37.26B | +0.4% |
| Q1 FY2019 | Mar 31, 2019 | $37.14B | -0.4% |
| Q4 FY2018 | Dec 31, 2018 | $40.31B | +7.9% |
| Q3 FY2018 | Sep 30, 2018 | $40.51B | +7.2% |
| Q2 FY2018 | Jun 30, 2018 | $37.11B | -0.3% |
| Q1 FY2018 | Mar 31, 2018 | $37.29B | +0.9% |
| Q4 FY2017 | Dec 31, 2017 | $37.37B | +1.4% |
| Q3 FY2017 | Sep 30, 2017 | $37.80B | +1.3% |
| Q2 FY2017 | Jun 30, 2017 | $37.24B | – |
| Q1 FY2017 | Mar 31, 2017 | $36.95B | – |
| Q4 FY2016 | Dec 31, 2016 | $36.84B | – |
| Q3 FY2016 | Sep 30, 2016 | $37.31B | – |
See a number that looks wrong?